Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,970,294

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $102.37 -0.21 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (202 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.

Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down

The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.

NextGen (NXGN) Q3 Earnings Fall Shy of Estimates, Revenues Top

NextGen's (NXGN) third-quarter fiscal 2023 results reflect strength in its Recurring revenues.

Here's Why You Should Retain DaVita (DVA) Stock for Now

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.

CVS Health (CVS) to Expand Health Care Access With New Pact

CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.

Quest Diagnostics (DGX) to Report Q4 Earnings: What's in Store?

Quest Diagnostics (DGX) ramps up investments to accelerate growth in the base business, particularly in advanced diagnostics and direct-to-consumer testing.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

Stryker's (SYK) fourth-quarter results are likely to reflect its strong segmental performances. However, rising costs are likely to have continued to have hurt margins during the quarter.

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

Veeva Systems' (VEEV) slew of product launches raises optimism about the stock.

Abbott's (ABT) New FDA Approval to Improve Patient Outcome

Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

Walgreens Boots (WBA) continues to progress in transforming the pharmacy business and the method of delivering healthcare through physical stores and digital channels.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

The industrywide trend of record-level inflation, supply issues and staffing shortages are expected to have deterred growth in several areas of Thermo Fisher's (TMO) business in Q4.

IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q4 owing to continued rise in Catalyst and premium hematology placements.

Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know

Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials

Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.

Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q1 Earnings

The growing adoption of Panther instruments worldwide will likely drive Hologic's (HOLX) Q1 revenues.

Intuitive Surgical (ISRG) to Post Q4 Earnings: What's in Store?

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies.

ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues

ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Cardinal Health (CAH) Gains As Market Dips: What You Should Know

Cardinal Health (CAH) closed at $76.47 in the latest trading session, marking a +0.07% move from the prior day.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome

Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

Align Technology's (ALGN) increased shipments in Invisalign case volumes across almost all markets are likely to benefit Q4 revenues.

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

Investors continue to be optimistic about Merit Medical (MMSI), owing to its strong product portfolio.